Investors however should be mindful of the risks with bio-tech companies. PPHM's immense upside hinges on securing the FDA's approval for its Bavituximab drug in the Sunrise Phase 3 Trial.
Read it here:
http://www.fool.com/investing/small-cap/2015/08/11/5-things-peregrine-pharmaceuticals-wants-you-to-kn.aspx
No comments:
Post a Comment